| Ribosomal protein S6 kinase 2 (RPS6KB2) is a potential immunotherapeutic target for cancer that upregulates proinflammatory cytokines. | Ribosomal protein S6 kinase 2 (RPS6KB2) is a potential immunotherapeutic target for cancer that upregulates proinflammatory cytokines.
Ma Q, Yang Y, Chen S, Cheng H, Gong P, Hao J. | 02/29/2024 |
| NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to temozolomide (TMZ) via NELFB and RPS6KB2 interaction. | NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to temozolomide (TMZ) via NELFB and RPS6KB2 interaction.
Awah CU, Winter J, Mazdoom CM, Ogunwobi OO., Free PMC Article | 01/15/2022 |
| Circ-GLI1 promotes metastasis in melanoma through interacting with p70S6K2 to activate Hedgehog/GLI1 and Wnt/beta-catenin pathways and upregulate Cyr61. | Circ-GLI1 promotes metastasis in melanoma through interacting with p70S6K2 to activate Hedgehog/GLI1 and Wnt/β-catenin pathways and upregulate Cyr61.
Chen J, Zhou X, Yang J, Sun Q, Liu Y, Li N, Zhang Z, Xu H., Free PMC Article | 03/27/2021 |
| Activation of Mechanistic Target of Rapamycin (mTOR) in Human Endothelial Cells Infected with Pathogenic Spotted Fever Group Rickettsiae. | Activation of Mechanistic Target of Rapamycin (mTOR) in Human Endothelial Cells Infected with Pathogenic Spotted Fever Group Rickettsiae.
Sahni A, Narra HP, Sahni SK., Free PMC Article | 03/6/2021 |
| Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer. | Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer.
Sridharan S, Basu A., Free PMC Article | 11/21/2020 |
| The results suggest that although the polyproline region of S6K2 is capable of generating ribosomal stalling, the depletion of eIF5A in HeLa cells seems to be insufficient to cause an expressive decrease in the content of endogenous S6K2. | The polyproline-motif of S6K2: eIF5A translational dependence and importance for protein-protein interactions.
Meneguello L, Barbosa NM, Pereira KD, Proença ARG, Tamborlin L, Simabuco FM, Iwai LK, Zanelli CF, Valentini SR, Luchessi AD. | 07/25/2020 |
| Role of S6K2 in cancer cell survival.[review] | S6K2 promises an important therapeutic potential for cancer.
Sever Nİ, Cengiz Şahin S. | 03/23/2019 |
| p54-S6K2 interactome is predominant to the nucleus, whereas p70-S6K1 is predominant to cytosol. | Different interactomes for p70-S6K1 and p54-S6K2 revealed by proteomic analysis.
Pavan IC, Yokoo S, Granato DC, Meneguello L, Carnielli CM, Tavares MR, do Amaral CL, de Freitas LB, Paes Leme AF, Luchessi AD, Simabuco FM. | 10/7/2017 |
| Overexpression of catalytically-active Akt or knockdown of glycogen synthase kinase-3 (GSK3)-beta, a substrate for Akt, had little effect on Mcl-1 downregulation caused by S6K2 deficiency | Regulation of anti-apoptotic Bcl-2 family protein Mcl-1 by S6 kinase 2.
Basu A, Sridharan S., Free PMC Article | 09/9/2017 |
| We propose that the S6K2/TRBP node controls miRNA biogenesis in HDLECs and provides a molecular link between the mTOR pathway and the miRNA biogenesis machinery. | S6K2-mediated regulation of TRBP as a determinant of miRNA expression in human primary lymphatic endothelial cells.
Warner MJ, Bridge KS, Hewitson JP, Hodgkinson MR, Heyam A, Massa BC, Haslam JC, Chatzifrangkeskou M, Evans GJ, Plevin MJ, Sharp TV, Lagos D., Free PMC Article | 06/10/2017 |
| discovered that ERBB4 and S6K2 were the direct targets of miR-193a-3p and that PIK3R3 and mTOR were the direct targets of miR-193a-5p in non-small-cell lung cancer | MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway.
Yu T, Li J, Yan M, Liu L, Lin H, Zhao F, Sun L, Zhang Y, Cui Y, Zhang F, Li J, He X, Yao M. | 04/11/2015 |
| Degradation of Tiam1 by casein kinase 1 and the SCFbetaTrCP ubiquitin ligase controls the duration of mTOR-S6K signaling. | Degradation of Tiam1 by casein kinase 1 and the SCFβTrCP ubiquitin ligase controls the duration of mTOR-S6K signaling.
Magliozzi R, Kim J, Low TY, Heck AJ, Guardavaccaro D., Free PMC Article | 12/20/2014 |
| The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer. | The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.
Karlsson E, Pérez-Tenorio G, Amin R, Bostner J, Skoog L, Fornander T, Sgroi DC, Nordenskjöld B, Hallbeck AL, Stål O., Free PMC Article | 09/13/2014 |
| The p85 S6K1 promotes H2O2-induced cell death via a rapamycin-insensitive mechanism. | IKK-β mediates hydrogen peroxide induced cell death through p85 S6K1.
Jia CH, Li M, Liu J, Zhao L, Lin J, Lai PL, Zhou X, Zhang Y, Chen ZG, Li HY, Liu AL, Yang CL, Gao TM, Jiang Y, Bai XC., Free PMC Article | 06/22/2013 |
| S6K2 amplification was frequently observed in gastric cancer and was related to a poor prognosis | Gene amplification of ribosomal protein S6 kinase-1 and -2 in gastric cancer.
Yoshida S, Matsumoto K, Arao T, Taniguchi H, Goto I, Hanafusa T, Nishio K, Yamada Y. | 04/13/2013 |
| S6K1 and S6K2 gene amplification was associated with a worse prognosis. | Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.
Pérez-Tenorio G, Karlsson E, Waltersson MA, Olsson B, Holmlund B, Nordenskjöld B, Fornander T, Skoog L, Stål O. | 09/15/2012 |
| S6K2 expression dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis | Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis.
Nardella C, Lunardi A, Fedele G, Clohessy JG, Alimonti A, Kozma SC, Thomas G, Loda M, Pandolfi PP., Free PMC Article | 07/23/2011 |
| Study shows that the two homologues of S6K have distinct effects on Akt activation and cell survivalin breast cancer. | S6 kinase 2 promotes breast cancer cell survival via Akt.
Sridharan S, Basu A., Free PMC Article | 07/16/2011 |
| Dysregulation of S6 kinases contributes to the pathogenesis of human diseases. | Functions and regulation of the 70kDa ribosomal S6 kinases.
Fenton TR, Gout IT. | 06/18/2011 |
| Data show that genetic variation in RPS6KA1, RPS6KA2, and PRS6KB2 were associated with risk of developing colon cancer while only genetic variation in RPS6KA2 was associated with altering risk of rectal cancer. | Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer.
Slattery ML, Lundgreen A, Herrick JS, Wolff RK, Slattery ML, Lundgreen A, Herrick JS, Wolff RK., Free PMC Articles: PMC3038588, PMC3038588 | 03/5/2011 |
| Observational study of gene-disease association. (HuGE Navigator) | Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer.
Slattery ML, Lundgreen A, Herrick JS, Wolff RK, Slattery ML, Lundgreen A, Herrick JS, Wolff RK., Free PMC Articles: PMC3038588, PMC3038588 | 12/5/2010 |
| Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator) | MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer.
Zhang X, Yang H, Lee JJ, Kim E, Lippman SM, Khuri FR, Spitz MR, Lotan R, Hong WK, Wu X., Free PMC Article | 12/5/2010 |
| heterogeneous ribonucleoprotein F is involved in the regulation of cell proliferation via the mammalian target of rapamycin/S6 kinase 2 pathway | Involvement of heterogeneous ribonucleoprotein F in the regulation of cell proliferation via the mammalian target of rapamycin/S6 kinase 2 pathway.
Goh ET, Pardo OE, Michael N, Niewiarowski A, Totty N, Volkova D, Tsaneva IR, Seckl MJ, Gout I., Free PMC Article | 06/28/2010 |
| S6K2 is active throughout the cell cycle with higher activity in G2 and M phases. | Regulation of catalytic activity of S6 kinase 2 during cell cycle.
Boyer D, Quintanilla R, Lee-Fruman KK., Free PMC Article | 01/21/2010 |
| the PI3K/p70 S6K/c-Myc cascade plays an important role in neutrophilic proliferation in HL-60 cells. | The role of c-Myc on granulocyte colony-stimulating factor-dependent neutrophilic proliferation and differentiation of HL-60 cells.
Kanayasu-Toyoda T, Yamaguchi T, Oshizawa T, Uchida E, Hayakawa T. | 01/21/2010 |